title: Inhibition of migration of human glioblastoma cells by cerivastatin in association with focal adhesion kinase (FAK).
abstract: To investigate the biological effect of cerivastatin on glioblastoma cells, we exposed them to various concentrations of cerivastatin. Cerivastatin exhibited dual effects on glioblastoma cells in a dose-dependent manner. Immunofluorescence microscopy showed disruption of actin stress fibers and focal adhesion plaques even at nanomolar concentrations. Matrigel assay demonstrated marked inhibition of glioblastoma cell invasion. Immunoblot analysis using a phosphospecific antibody against focal adhesion kinase (FAK) showed that inhibition of migration was associated with the down-regulation of tyrosine phosphorylation of FAK. Our data suggest that cerivastatin may be beneficial for combination therapy with conventional anti-cancer drugs by inhibiting the invasion of glioblastoma.
authors.affiliation: Department of Neurosurgery, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, 890-8520, Kagoshima, Japan. sochian@ta2.so-net.ne.jp
authors.forename: Soichi
authors.initials: S
authors.lastname: Obara
authors.forename: Masanori
authors.initials: M
authors.lastname: Nakata
authors.forename: Hideo
authors.initials: H
authors.lastname: Takeshima
authors.forename: Jun-ichi
authors.initials: J
authors.lastname: Kuratsu
authors.forename: Ikuro
authors.initials: I
authors.lastname: Maruyama
authors.forename: Isao
authors.initials: I
authors.lastname: Kitajima
mesh_terms: D001932:Brain Neoplasms / Q000201:enzymology / Q000473:pathology*; D002448:Cell Adhesion / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D003094:Collagen; D003864:Depression, Chemical; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004354:Drug Screening Assays, Antitumor; D004790:Enzyme Induction / Q000187:drug effects; D051417:Focal Adhesion Kinase 1; D051416:Focal Adhesion Protein-Tyrosine Kinases; D022001:Focal Adhesions / Q000187:drug effects; D005909:Glioblastoma / Q000201:enzymology / Q000473:pathology*; D006801:Humans; D007797:Laminin; D008856:Microscopy, Fluorescence; D009361:Neoplasm Invasiveness; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000502:physiology*; D010766:Phosphorylation / Q000187:drug effects; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D011505:Protein-Tyrosine Kinases / Q000096:biosynthesis / Q000502:physiology*; D011509:Proteoglycans; D011725:Pyridines / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects; D022502:Stress Fibers / Q000187:drug effects; D014407:Tumor Cells, Cultured / Q000166:cytology / Q000187:drug effects
chemical_list: D004338:Drug Combinations; D007797:Laminin; D009363:Neoplasm Proteins; D011509:Proteoglycans; D011725:Pyridines; C059485:matrigel; D003094:Collagen; C086276:cerivastatin; D011505:Protein-Tyrosine Kinases; D051417:Focal Adhesion Kinase 1; D051416:Focal Adhesion Protein-Tyrosine Kinases; C496050:PTK2 protein, human